Azacyclic compounds

Abstract

Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is adminstered to a patient in need of such treatment.

1 .- 52 . (canceled) 
     
     
         53 . A compound of formula (I) 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, wherein 
         Z is 
       
       
         
           
           
               
               
           
         
         
           in which 
           R is a hydrogen, a lower alkyl group, a cyclic organyl group, or a substituted or unsubstituted aralkyl or heteroaralkyl group; and 
           n is 1; 
           X 1  is methylene, vinylene, or an NH or N (lower alkyl) group; 
           X 2  is methylene, or, when X 1  is methylene or vinylene, X 2  is methylene or a bond; or 
           when X 1  is methylene, X 2  is O, S, NH, or N(lower alkyl) or a bond; 
           Y 1  is methylene and Y 2  is methylene, vinylene, ethylene, propylene, or a bond; or 
           Y 1  is a bond and Y 2  is vinylene; or 
           Y 1  is ethylene and Y 2  is O, S, NH, or N (lower alkyl); 
           Ar 1  and Ar 2  are independently unsubstituted or substituted phenyl groups; and 
           W is oxygen. 
         
       
     
     
         54 . The compound or pharmaceutically acceptable salt of  claim 53 , wherein R is a lower alkyl group. 
     
     
         55 . The compound or pharmaceutically acceptable salt of  claim 54 , wherein R is selected from the group consisting of methyl, ethyl, propyl, butyl, methylbutyl, cyclopropyl, cyclohexyl, iso-propyl and tert-butyl. 
     
     
         56 . The compound or pharmaceutically acceptable salt of  claim 53 , wherein Ar 1  and Ar 2  are unsubstituted phenyl groups. 
     
     
         57 . The compound or pharmaceutically acceptable salt of  claim 53 , wherein Ar 1  is an unsubstituted phenyl group and Ar 2  is a phenyl group substituted with one or more substituents selected from the group consisting of halo, hydroxy, amino, cyano, nitro, alkylamido, acyl, lower alkoxy, lower alkyl, lower hydroxyalkyl, lower aminoalkyl, lower alkylamino, alkylsulfenyl, alkylsulfinyl, alkyl sulfonyl, sulfamoyl, and trifluoromethyl. 
     
     
         58 . The compound or pharmaceutically acceptable salt of  claim 53 , wherein Ar 2  is an unsubstituted phenyl group and Ar 1  is a phenyl group substituted with one or more substituents selected from the group consisting of halo, hydroxy, amino, cyano, nitro, alkylamido, acyl, lower alkoxy, lower alkyl, lower hydroxyalkyl, lower aminoalkyl, lower alkylamino, alkylsulfenyl, alkylsulfinyl, alkyl sulfonyl, sulfamoyl, and trifluoromethyl. 
     
     
         59 . The compound or pharmaceutically acceptable salt of  claim 53 , wherein Ar 1  and Ar 2  are phenyl groups independently substituted with one or more substituents selected from the group consisting of halo, hydroxy, amino, cyano, nitro, alkylamido, acyl, lower alkoxy, lower alkyl, lower hydroxyalkyl, lower aminoalkyl, lower alkylamino, alkylsulfenyl, alkylsulfinyl, alkylsulfonyl, sulfamoyl, and trifluoromethyl.